Expertise in
3
conditions

Bart D. Maes

Roeselare, VLG, BE 
Expertise in
3
conditions
Roeselare, VLG, BE 

Overview

Bart Maes practices practicing medicine in Roeselare, Belgium.

Mr. Maes is highly rated in 3 conditions, according to our data. His clinical expertise encompasses IgA Nephropathy, Glomerulonephritis, Malakoplakia, Diphtheria, and Kidney Transplant.

He is actively involved in clinical research, co-authoring 29 peer reviewed articles and participating in 2 clinical trials.

Gender

Male

Locations

Roeselare, VLG, Belgium
Other Locations
Beerse, VLG 2340, Belgium

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Phase 3 Randomized, Open-label (Sponsor-blind), Active-controlled, Parallel-group, Multi-center, Event Driven Study in Non-dialysis Subjects With Anemia Associated With Chronic Kidney Disease to Evaluate the Safety and Efficacy of Daprodustat Compared to Darbepoetin Alfa
A Phase 3 Randomized, Open-label (Sponsor-blind), Active-controlled, Parallel-group, Multi-center, Event Driven Study in Non-dialysis Subjects With Anemia Associated With Chronic Kidney Disease to Evaluate the Safety and Efficacy of Daprodustat Compared to Darbepoetin Alfa
Enrollment Status: Completed
Publish Date: April 02, 2024
Intervention Type: Drug
Study Drugs: Daprodustat, Darbepoetin Alpha
Study Phase: Phase 3
Metformin as RenoProtector in Non-Diabetic Patients With Progressive Chronic Kidney Disease (CKD Stages 2, 3A and 3B): a Multi-centre, Practice-oriented, Repurposing, Double-blind, Placebo-controlled, Randomized Clinical Trial
Metformin as RenoProtector in Non-Diabetic Patients With Progressive Chronic Kidney Disease (CKD Stages 2, 3A and 3B): a Multi-centre, Practice-oriented, Repurposing, Double-blind, Placebo-controlled, Randomized Clinical Trial
Enrollment Status: Unknown
Publish Date: December 19, 2023
Intervention Type: Drug
Study Phase: Phase 3
View 1 Less Clinical Trial

29 Total Publications

Iptacopan in IgA Nephropathy - Final 24-Month Data.
Iptacopan in IgA Nephropathy - Final 24-Month Data.
Journal: The New England journal of medicine
Published: March 30, 2026

Frequently Asked Questions about Bart D. Maes

Is Bart D. Maes a top-rated expert for IgA Nephropathy?

MediFind is an objective health platform that identifies experts based on real-world data. Bart D. Maes is classified as an Distinguished expert for IgA Nephropathy, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Bart D. Maes participate in research or clinical trials?

Yes. Bart D. Maes has published 29 articles and abstracts on conditions like IgA Nephropathy. You can view a list of Bart D. Maes's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Maes's expertise for a condition
ConditionClose
    View All 11 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile